Dis-Chem has issued a trading update on Monday, 26 May 2025, offering investors a preview of its anticipated financial performance for the year ended 28 February 2025.

The pharmaceutical and retail chain projects its earnings per share (EPS) and headline earnings per share (HEPS) will fall between 136.4 cents and 138.8 cents. This reflects a solid year-on-year rise of between 19% and 21%, up from the 114.7 cents (EPS) and 114.6 cents (HEPS) posted in the 2024 financial year.

This update builds on a previous trading statement released in February, which covered performance from 1 September 2024 through 31 January 2025. During that time, Dis-Chem noted a boost in sales activity in January, attributed to customers accessing their renewed medical aid benefits.

For the five-month period, total retail revenue climbed 5.6%, while comparable store sales—those open for at least a year—advanced by 2.9%.

CEO Rui Morais commented on the rebound: “January’s recovery in retail revenue, largely due to renewed medical aid spending, continued through February and helped offset softer trading during November.”

He also highlighted effective cost control measures: “We’ve made encouraging progress in managing our biggest cost line—retail staffing—leading to better operational leverage and contributing to the earnings growth achieved in the first half.”

Dis-Chem has also strengthened its leadership in South Africa’s pharmacy sector, growing its share of the dispensary market and maintaining its status as the country’s largest retail pharmacy group by dispensary volume.

Currently, the company operates 333 retail outlets nationwide, consisting of 286 Dis-Chem Pharmacy locations and 47 Dis-Chem Baby City branches.

The company is scheduled to publish its full-year results for the 2025 fiscal year on Friday, 30 May 2025.

Whatsapp